N-linked glycosylation is a critical determinant of
protein structure and function, regulating processes such as protein folding, stability and localization,
ligand-receptor binding and intracellular signalling. TβRII [type II TGF-β (
transforming growth factor β) receptor] plays a crucial role in the TGF-β signalling pathway. Although N-linked glycosylation of TβRII was first demonstrated over a decade ago, it was unclear how this modification influenced TβRII biology. In the present study, we show that inhibiting the N-linked glycosylation process successfully hinders binding of TGF-β1 to TβRII and subsequently renders cells resistant to TGF-β signalling. The
lung cancer cell line A549, the gastric
carcinoma cell line MKN1 and the immortal cell line HEK (human embryonic kidney)-293 exhibit reduced TGF-β signalling when either treated with two inhibitors, including
tunicamycin (a potent N-linked glycosylation inhibitor) and
kifunensine [an inhibitor of ER (endoplasmic reticulum) and Golgi
mannosidase I family members], or introduced with a non-glycosylated mutant version of TβRII. We demonstrate that defective N-linked glycosylation prevents TβRII
proteins from being transported to the cell surface. Moreover, we clearly show that not only the complex type, but also a high-
mannose type, of TβRII can be localized on the cell surface. Collectively, these findings demonstrate that N-linked glycosylation is essentially required for the successful cell surface transportation of TβRII, suggesting a novel mechanism by which the TGF-β sensitivity can be regulated by N-linked glycosylation levels of TβRII.